EDGAR Filing Documents for 0001104659-22-053526

Form SC 13G - Statement of acquisition of beneficial ownership by individuals:

SEC Accession No. 0001104659-22-053526

Filing Date

2022-04-29

Accepted

2022-04-29 16:05:55

Documents

Group Members

KOH, BONGSHAH, NIMISHVENROCK HEALTHCARE CAPITAL PARTNERS EG, L.P.VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P.VHCP CO-INVESTMENT HOLDINGS II, LLCVHCP CO-INVESTMENT HOLDINGS III, LLCVHCP MANAGEMENT EG, LLCVHCP MANAGEMENT II, LLCVHCP MANAGEMENT III, LLC

Document Format Files

Seq	Description	Document	Type	Size
1	SC 13G	tm2214022d1_sc13g.htm	SC 13G	270178
	Complete submission text file	0001104659-22-053526.txt		272190

Mailing Address 7 BRYANT PARK 23RD FLOOR NEW YORK NY 10018

Business Address 7 BRYANT PARK 23RD FLOOR NEW YORK NY 10018 650 475 3734

Venrock Healthcare Capital Partners II, L.P. (Filed by) CIK: 0001602264 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210

Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340

Inozyme Pharma, Inc. (Subject) CIK: 0001693011 (see all company filings)